FGF23 and X-linked dominant hypophosphatemic rickets: An important novelty in the treatment of XLHR was the introduction of burosumab (KRN23), a recombinant human monoclonal IgG1 antibody that targets FGF23, restoring renal Napi co-transporter [14].